- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mi | Aclarion, Inc.: Aclarion Wins "Rising Star" at 2025 Digital Health Hub Foundation: Digital Health Awards at HLTH | 1 | GlobeNewswire (USA) | ||
| 14.10. | Aclarion reports 89% increase in Nociscan scan volumes in Q3 | 1 | Investing.com | ||
| 14.10. | Aclarion, Inc.: Aclarion Provides Corporate Update Highlighting Market Expansion as CLARITY Trial Advances Toward Key Data Catalyst | 117 | GlobeNewswire (Europe) | Debt-free balance sheet with $13.3 million in cash as of today ($15.11 per share fully diluted) providing strategic flexibility for continued commercial growth Nociscan scan volumes increase +89%... ► Artikel lesen | |
| 14.10. | Aclarion, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 13.10. | Aclarion Stock Rises 32% After Global Pain Conference Presentation | 1 | RTTNews | ||
| 13.10. | Teilnahme an Fachkonferenz beflügelt Aclarion-Aktie | 1 | Investing.com Deutsch | ||
| 13.10. | Aclarion stock soars after participation in international pain meeting | 2 | Investing.com | ||
| 13.10. | XFRA MISTRADE ANTRAG IN ISIN US6551874091 WURDE ABGELEHNT | 188 | Xetra Newsboard | Der Mistrade-Antrag wurde abgelehnt. Folgende Geschaefte in der ISIN US6551874091, Wertpapier-Name: ACLARION NEW DL-,00001, werden nicht aufgehoben:Datum Zeit Volumen Preis13.10.2025 10:01:46 400 8,8 ► Artikel lesen | |
| ACLARION Aktie jetzt für 0€ handeln | |||||
| 13.10. | XFRA MISTRADE ANTRAG IN ISIN US6551874091 WIRD GEPRUEFT | 161 | Xetra Newsboard | Fuer folgende Geschaefte in der ISIN US6551874091, Wertpapier-Name: ACLARION NEW DL-,00001, wird ein Mistrade-Antrag geprueft:Datum Zeit Volumen Preis13.10.2025 10:01:46 400 8.8Fair Value lt. Antragsteller:... ► Artikel lesen | |
| 09.10. | Aclarion to Present at the LD Micro Main Event XIX | 221 | Newsfile | Broomfield, Colorado--(Newsfile Corp. - October 9, 2025) - Aclarion, Inc. (NASDAQ: ACON) (NASDAQ: ACONW) ("Aclarion" or the "Company"), a healthcare technology company that is leveraging biomarkers... ► Artikel lesen | |
| 07.10. | Aclarion, Inc.: Aclarion Honored as Finalist for the 2025 Digital Health Hub Foundation: Digital Health Awards at HLTH | 1 | GlobeNewswire (USA) | ||
| 01.10. | Aclarion, Inc.: Aclarion Presents at LSI Europe '25 Highlighting Nociscan Technology and Key Value Drivers | 2 | GlobeNewswire (USA) | ||
| 25.09. | Aclarion, Inc.: First Patients Enrolled at UHealth - University of Miami in Aclarion's Pivotal CLARITY Trial | 2 | GlobeNewswire (USA) | ||
| 19.09. | Aclarion stock price target raised to $22 from $20 by Ascendiant Capital | 2 | Investing.com | ||
| 03.09. | Aclarion, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 03.09. | Aclarion taps Greg Gould as CFO | 1 | Seeking Alpha | ||
| 03.09. | Aclarion names Greg Gould as new CFO to drive growth strategy | 1 | Investing.com | ||
| 03.09. | Aclarion, Inc.: Aclarion Appoints Greg Gould as Chief Financial Officer | 98 | GlobeNewswire (Europe) | HealthTech CFO with extensive public company experience building organizations for growth and value creation Demonstrated success in raising capital, driving profitability, and scaling operations... ► Artikel lesen | |
| 14.08. | Aclarion, Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 05.08. | Aclarion, Inc.: Aclarion Provides Corporate Update Highlighting Scan Volume Growth and Key Upcoming Catalysts | 134 | GlobeNewswire (Europe) | Nociscan YOY scan volume increased 132% from Q2 2024 to Q2 2025 fueled by new physician adoption and insurance company coverage in the UK Company has achieved two consecutive quarters of scan volume... ► Artikel lesen |
1 2 3 Weiter >>
42 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| UNITEDHEALTH | 312,00 | +0,10 % | Nächstes Beben: Molina Healthcare crasht - UnitedHealth schwach | Die US-Krankenversicherer kommen nicht zur Ruhe. Am Mittwochabend hat der Gesundheitsdienstleister Molina Healthcare die Anleger mit enttäuschenden Zahlen erneut verunsichert. Die Aktie brach daraufhin... ► Artikel lesen | |
| INTUITIVE SURGICAL | 470,85 | +0,19 % | Intuitive Surgical-Aktie +16%: Kommt das große Comeback? | Nachdem die Intuitive Surgical-Aktie bereits am Montag und Dienstag in Summe um fast +8% zugelegt hat, schießt sie am Mittwochmorgen um +16% in die Höhe. Was steckt hinter dem großen Kurssprung des... ► Artikel lesen | |
| THERMO FISHER | 494,00 | +0,36 % | Biotech-Investoren sollten diese Zulieferer kennen: Thermo Fisher Scientific, BioNxt, AptarGroup | Während neue Medikamente die Schlagzeilen dominieren, sind es oft Zulieferer und Serviceanbieter, die langfristig solide Renditen liefern. Drei Beispiele: Thermo Fisher Scientific, BioNxt Solutions... ► Artikel lesen | |
| ROKU | 83,37 | +0,69 % | Roku may have finally fixed the biggest headache in TV streaming - here's how | ||
| ATOSSA THERAPEUTICS | 0,782 | -2,49 % | Atossa Therapeutics Inc: Atossa Appoints Mark Daniel, CPA, as Chief Financial Officer to Lead Finance, Systems, and Capital Strategy for Commercial Readiness | 25+ year life-sciences finance leader brings revenue-forecasting rigor, public-company controls, and capital-markets experience as Atossa prepares for commercial... ► Artikel lesen | |
| EVOFEM BIOSCIENCES | - | - | Evofem Biosciences, Inc.: Evofem Announces Voting Results from Special Meeting of Stockholders | -- Evofem Shareholders Did Not Approve the Merger with Aditxt --
-- Evofem Pivots to Target National Listing for Stock, Growth Capital to Catalyze Net Sales... ► Artikel lesen | |
| CENTENE | 29,405 | +0,46 % | Centene CEO: ICHRA Is the Future of Individual Health Insurance | ||
| QUIDELORTHO | 26,000 | -1,52 % | QuidelOrtho Corporation: QuidelOrtho Completes Debt Refinancing | SAN DIEGO, Aug. 21, 2025 /PRNewswire/ -- QuidelOrtho Corporation (Nasdaq: QDEL) (the "Company" or "QuidelOrtho"), a global provider of innovative in-vitro diagnostic... ► Artikel lesen | |
| VERU | 3,790 | +2,43 % | Veru Inc.: Veru Reports Fiscal 2025 Third Quarter Financial Results and Clinical Program Progress | --Company reported positive efficacy and safety data from Phase 2b QUALITY study showing enobosarm added to semaglutide led to preservation of muscle, greater fat loss, and fewer gastrointestinal... ► Artikel lesen | |
| TEMPEST THERAPEUTICS | 6,010 | -100,00 % | Tempest Therapeutics: Tempest Reports Second Quarter 2025 Financial Results and Provides Business Update | Received clearance to proceed with pivotal trial of amezalpat combination therapy for first-line hepatocellular carcinoma (HCC) in ChinaGranted orphan drug designation from the European Medicines... ► Artikel lesen | |
| NANO-X IMAGING | 4,055 | -0,86 % | Nano-X Imaging LTD.: Nanox Announces Clinical and Educational Collaboration with Keiser University Featuring the Nanox.ARC | Nanox.ARC delivers advanced 3D imaging with proprietary cold cathode technologyClinical studies show superior diagnostic performance to X-ray with reduced radiation exposure compared to CT PETACH... ► Artikel lesen | |
| FULGENT GENETICS | 20,200 | +1,00 % | Fulgent Genetics meldet positive Studiendaten bei Kopf- und Halskrebs | ||
| LANTHEUS | 48,860 | +1,39 % | Lantheus And GE HealthCare Sign Licensing Deal For PYLARIFY In Japan | WASHINGTON (dpa-AFX) - Lantheus Holdings Inc. (LNTH) and GE HealthCare (GEHC) announced an exclusive licensing agreement under which GE HealthCare will develop, manufacture, and commercialize... ► Artikel lesen | |
| PERSPECTIVE THERAPEUTICS | 2,540 | -0,78 % | Perspective Therapeutics, Inc.: Perspective Therapeutics to Provide Business Highlights and Report Third Quarter 2025 Financial Results | ||
| AMN HEALTHCARE SERVICES | 17,300 | +6,14 % | AMN Healthcare Services Inc: AMN Healthcare Announces Second Quarter 2025 Results | Quarterly revenue of $658 million and Adjusted EBITDA of $58.3 million; GAAP loss of ($3.02)/share and adjusted EPS of $0.30 DALLAS, Aug. 07, 2025 (GLOBE NEWSWIRE) -- AMN Healthcare Services, Inc.... ► Artikel lesen |
ACLARION INC gehört der Branche Gesundheitswesen an. Die relative Kursveränderung beträgt aktuell +0,32 % bei einem Aktienkurs von 6,360 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ACLARION INC finden Sie auf Wallstreet Online.